News on a retrospective report on two patients with late-onset neutropenia (LON) showed an uncommon adverse event following the use of anti-CD20 treatment.1 Treatment for neuroinflammatory conditions are increasingly being used with anti-CD20 therapies and as before the report it was not explored for patients with LON as it is a rare complication following the therapies.2
Based on the data from the report of the only two patients with LON over a 7-year period, the incidence rate was 11%.1 Then respectively, 1.7% was the rate for using the treatments of the ocrelizumab (Ocrevus; Genentech) and rituximab (Rituxan; Genentech; Biogen) for patients with LON. Overall, for the use of anti-CD20 treatment for patients with LOD was a 3.0% rate.
Lead investigator, Christen Sheng JieLim, MBBS, MRCP, MMED, associate consultant, National Neuroscience Institute, and colleagues wrote, “The first patient had relapsing remitting MS and developed LON 14 weeks after receiving her third dose of ocrelizumab, while the second patient had Aquaporin-4 antibody NMOSD and developed LON 4 weeks after the third dose of rituximab. Both had tolerated the initial 2 doses of their respective therapies without complications.”1
A retrospective chart review was performed and collected eligible patients, who had both neuroinflammatory conditions and received antiCD20 therapies, from the National Neuroscience Institute between January 2015 and December 2021. From the data, there were 77 patients found who identified either as having multiple sclerosis (MS; n = 41) or neuromyelitis optica spectrum disorder (NMOSD; n = 26). Only 9 patients with MS had ocrelizumab as a treatment whereas the rest of the patients (MS and NMOSD, n = 58) were given rituximab.
During the period of neutropenia for both patients, antibiotics were administered, and the patients received a course of granulocyte colony as a stimulating factor following the development of pyrexia. Afterward, the patients both had a short recovery and received even more anti-CD20 therapies with there being no LON recurrence.